Illumina's Q2 Sales Rise 36 Percent on Sequencing Demand, 'Overall Improvement' in Array Sales
August 02, 2011
Illumina's Q2 Sales Rise 36 Percent on Sequencing Demand, 'Overall Improvement' in Array Sales
The firm credited "strong demand" for its next-gen-sequencing tools and restored growth in its array business, particularly for whole-genome genotyping chips for the spike in sales.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina Predicts Flat Future for Array Business as GWAS Decline Counters Growth in New Markets
October 30, 2012 / BioArray News - Illumina to Remain Secure if NIH Budget Shrinks as Projected, CEO Predicts
September 20, 2011 / BioArray News - Q&A: NCI's Stephen Chanock on the Three Waves of Genome-Wide Association Studies
March 1, 2011 / BioArray News - At Investor Confab, Illumina Details 'Enormous' DTC Demand as Market Shifts to Less Complex Chips
May 21, 2013 / BioArray News - GeneSeek Sees 'Double-Digit' Growth in Demand for Agrigenomics SNP Array Services
January 29, 2013 / BioArray News